TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11969276

Group type: EXPERIMENTAL
Intervention: Coronary heart disease risk factors in men
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Coronary heart disease risk factors in women
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Population-attributable risks in men
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Population-attributable risks in women
Number of subjects: 12000
Study: 9788403

Group type: EXPERIMENTAL
Intervention: Class I (583 patients)
Number of subjects: 1547

Group type: EXPERIMENTAL
Intervention: Class II (667 patients)
Number of subjects: 1547

Group type: EXPERIMENTAL
Intervention: Class III (249 patients)
Number of subjects: 1547

Group type: EXPERIMENTAL
Intervention: Class IV (48 patients)
Number of subjects: 1547
Study: 8004358

Group type: EXPERIMENTAL
Intervention: 2.7 g 3‐sn‐polyenylphosphatidylcholine (PPC) daily, orally for 2 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2682593

Group type: EXPERIMENTAL
Intervention: 50 mg amitriptyline (AMI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 mg Org 3770 (ORG)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 mg diazepam (DZ)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of AMI and DZ
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of ORG and DZ
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29948573

Group type: EXPERIMENTAL
Intervention: Mail-out healthcare surveys with varying questionnaire lengths (48-127 items)
Number of subjects: 0
Study: 28973076

Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin dietary supplementation (2 daily capsules) for 6 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 26173631

Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 mg
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: Eltrombopag 100 mg
Number of subjects: 1463
Study: 23303873

Group type: EXPERIMENTAL
Intervention: B‐GOS (galactooligosaccharide mixture)
Number of subjects: 45
Study: 21112898

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT-ON)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Optimal Medical Therapy (CRT-OFF)
Number of subjects: 262
Study: 18956206

Group type: EXPERIMENTAL
Intervention: Cephalometric analysis using radiographs
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Craniofacial computed tomography (CT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 17118507

Group type: EXPERIMENTAL
Intervention: Antibacterial toothbrush with triclosan
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular toothbrush
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Antibacterial toothbrush with toothpaste
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular toothbrush with toothpaste
Number of subjects: 10

Group type: COMPARATOR
Intervention: Antibacterial toothbrush without toothpaste
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular toothbrush without toothpaste
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Antibacterial toothbrush
Number of subjects: 10
Study: 15078238

Group type: EXPERIMENTAL
Intervention: Active nicotine patch (AP, 15 mg daily, n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo patch (PP, n = 100)
Number of subjects: 200
Study: 11259927

Group type: EXPERIMENTAL
Intervention: Becaplermin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9271009

Group type: EXPERIMENTAL
Intervention: EGFR overexpression in laryngeal SCC (n = 20; 83%)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metastatic laryngeal SCC (N = 5)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Laryngeal carcinoma cases with EGFR overexpression
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vocal cord polyps
Number of subjects: 24
Study: 7509371

Group type: EXPERIMENTAL
Intervention: Subliminal pregnancy message
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subliminal penetration message
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supraliminal pregnancy message
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supraliminal penetration message
Number of subjects: 100
Study: 2691481

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate (Augmentin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mezlocillin
Number of subjects: 0
Study: 235835

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall evaluation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Radiologic improvement
Number of subjects: 20
Study: 31290404

Group type: EXPERIMENTAL
Intervention: Web-delivered growth mindset intervention plus smoking cessation app
Number of subjects: 398

Group type: COMPARATOR
Intervention: Smoking cessation app alone
Number of subjects: 398
Study: 28459069

Group type: EXPERIMENTAL
Intervention: Bicarbonate hemodialysis (BHD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Online hemodiafiltration (HDF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 10
Study: 25410416

Group type: EXPERIMENTAL
Intervention: Stress procedure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 40
Study: 24078934

Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 120

Group type: COMPARATOR
Intervention: Other positions (supine and right lateral)
Number of subjects: 120
Study: 16966390

Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg/kg) plus midazolam (0.1 mg/kg; max: 2.5 mg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Nitrous oxide (50%)/oxygen (50%) plus hematoma block (2.5 mg/kg of 1% buffered lidocaine)
Number of subjects: 102
Study: 15259923

Group type: EXPERIMENTAL
Intervention: Mammogram for women with painful breasts
Number of subjects: 726

Group type: COMPARATOR
Intervention: Control group mammogram
Number of subjects: 726
Study: 10717781

Group type: EXPERIMENTAL
Intervention: Unprotected intercourse
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intact condoms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Punctured condoms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Failed condoms
Number of subjects: 12
Study: 7546527

Group type: EXPERIMENTAL
Intervention: Continuous hemodiafiltration
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional dialysis
Number of subjects: 87
Study: 1743624

Group type: EXPERIMENTAL
Intervention: CHOEP (cyclophosphamide 750 mg/m2 iv d 1, doxorubicin 50 mg/m2 iv d 1, vincristine 2 mg iv d 1, etoposide 100 mg/m2 iv d 3‐5, prednisolone 100 mg po d 1‐5)
Number of subjects: 146

Group type: COMPARATOR
Intervention: hCHOP alternating with IVEP (cyclophosphamide 1200 mg/m2 iv d 1, doxorubicin 40 mg/m2 iv d 1 + 2, vincristine 2 mg iv d 1, prednisolone 100 mg po d 1‐5; ifosfamide 1500 mg/m2 iv d 1‐5, vindesine 3 mg/m2 iv d 1, etoposide 120 mg/m2 iv d 3‐5, prednisolone 100 mg po d 1‐5)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 146
Study: 7075652

Group type: EXPERIMENTAL
Intervention: Alinidine 40 mg orally
Number of subjects: 6
Study: 30852696

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS on the unaffected hemisphere and physiotherapy (PT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation and physiotherapy (PT)
Number of subjects: 20
Study: 28467363

Group type: EXPERIMENTAL
Intervention: MedDiet + EVOO
Number of subjects: 5802

Group type: EXPERIMENTAL
Intervention: MedDiet + Nuts
Number of subjects: 5802

Group type: COMPARATOR
Intervention: Control (low-fat diet)
Number of subjects: 5802
Study: 26524223

Group type: EXPERIMENTAL
Intervention: Capacitive mode of 448 kHz radiofrequency therapy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Resistive mode of 448 kHz radiofrequency therapy
Number of subjects: 15
Study: 23188377

Group type: EXPERIMENTAL
Intervention: Lung transplantation
Number of subjects: 0
Study: 21449990

Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation irrigated with essential oils (EOs)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ultrasonic instrumentation irrigated with negative control
Number of subjects: 64
Study: 18640992

Group type: EXPERIMENTAL
Intervention: Group 1 (morphine 1 mg/ml, nalbuphine 0 mg/ml)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Group 2 (morphine 0.75 mg/ml, nalbuphine 0.25 mg/ml)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Group 3 (morphine 0.5 mg/ml, nalbuphine 0.5 mg/ml)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Group 4 (morphine 0.25 mg/ml, nalbuphine 0.75 mg/ml)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Group 5 (morphine 0 mg/ml, nalbuphine 1 mg/ml)
Number of subjects: 311
Study: 16365183

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus IFL (irinotecan, fluorouracil, and leucovorin)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 813

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 813
Study: 12809966

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ritonavir 600 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg and Ritonavir 600 mg
Number of subjects: 21
Study: 11253328

Group type: EXPERIMENTAL
Intervention: Normothermic CPB
Number of subjects: 132

Group type: COMPARATOR
Intervention: Hypothermic CPB
Number of subjects: 132
Study: 8888305

Group type: EXPERIMENTAL
Intervention: Unilateral discrimination (one hand)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bilateral discrimination (both hands)
Number of subjects: 0
Study: 1848170

Group type: EXPERIMENTAL
Intervention: Single intravenous injection of inulin (70 mg/kg over 5 min)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Single injection method
Number of subjects: 47
Study: 6407314

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85
Study: 31887792

Group type: EXPERIMENTAL
Intervention: Stereoscopic 3D AR model
Number of subjects: 58

Group type: COMPARATOR
Intervention: Monoscopic 3D desktop model
Number of subjects: 58

Group type: COMPARATOR
Intervention: 2D anatomical atlas
Number of subjects: 58
Study: 30986760

Group type: EXPERIMENTAL
Intervention: Coloxyl with senna BD from day one (Regimen A)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Coloxyl with senna +20 ml lactulose BD commencing on day 3 (Regimen B)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Coloxyl with senna tablets +20 ml lactulose BD commencing on day 6 (Regimen C)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Overall comparison of insertion rates across all regimens
Number of subjects: 570

Group type: COMPARATOR
Intervention: Other major constipation‐ or diarrhea‐associated complications
Number of subjects: 570

Group type: COMPARATOR
Intervention: Major patient‐centred outcomes
Number of subjects: 570
Study: 30230517

Group type: EXPERIMENTAL
Intervention: High self-efficacy for exercise, absence of depressive symptoms, strong social support
Number of subjects: 31

Group type: COMPARATOR
Intervention: RCAC residents
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 31
Study: 26194265

Group type: EXPERIMENTAL
Intervention: 27-Fr bougie
Number of subjects: 126

Group type: COMPARATOR
Intervention: 39-Fr bougie
Number of subjects: 126
Study: 24552888

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 8331

Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 8331

Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 8331
Study: 22341603

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 19037719

Group type: EXPERIMENTAL
Intervention: Single session condom promotion Internet intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (clinic sample)
Number of subjects: 0
Study: 17187586

Group type: COMPARATOR
Intervention: ATI-7505 20 mg t.i.d.
Number of subjects: 36

Group type: COMPARATOR
Intervention: ATI-7505 10 mg t.i.d.
Number of subjects: 36

Group type: COMPARATOR
Intervention: ATI-7505 10 and 20 mg t.i.d.
Number of subjects: 36
Study: 16318050

Group type: EXPERIMENTAL
Intervention: Lornoxicam (xefocam, 16 mg/day)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ketorolac (ketanov, 60-90 mg/day)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ketoprofen/ketonal (200 mg/day)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ketoprofen/artrozilene (320 mg/day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no NSAIDs)
Number of subjects: 140
Study: 11916781

Group type: EXPERIMENTAL
Intervention: Terlipressin combined with ephedrine (n = 19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ephedrine alone (n = 21)
Number of subjects: 40
Study: 9475848

Group type: EXPERIMENTAL
Intervention: 8-h euoxic hypercapnia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (air)
Number of subjects: 0
Study: 7543180

Group type: EXPERIMENTAL
Intervention: Xylometazoline hydrochloride (Otrivin Nasal Drops 0.1% or Pediatric Nasal Drops 0.05%)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (only myringotomy and ventilation tube insertion)
Number of subjects: 72
Study: 2366136

Group type: EXPERIMENTAL
Intervention: Penicillin (10 million units intravenously) and tetracycline (0.25 g intramuscularly) for 12 hours
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Penicillin (10 million units intravenously) and tetracycline (0.25 g intramuscularly) for 12 hours followed by oral ampicillin (2 g) and tetracycline (1.5 g) per day for 60 hours
Number of subjects: 96
Study: 639708

Group type: EXPERIMENTAL
Intervention: Furosemide (80 mg, single daily dose) given on the 12th, 13th, and 14th day of digoxin treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of furosemide with beta-methyl-digoxin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Furosemide given ten hours after the last digoxin dose
Number of subjects: 20
Study: 31262691

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment (group B2)
Number of subjects: 1745

Group type: EXPERIMENTAL
Intervention: No treatment (group B1)
Number of subjects: 1745

Group type: COMPARATOR
Intervention: Normal TSH levels (group A)
Number of subjects: 1745
Study: 29045983

Group type: EXPERIMENTAL
Intervention: BATHE intervention (daily for five days or until discharge)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 25
Study: 25496178

Group type: EXPERIMENTAL
Intervention: BNO 1016 (3 × 160 mg daily for 15 days)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Placebo (3 × placebo daily for 15 days)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: BNO 1016
Number of subjects: 589
Study: 23808982

Group type: EXPERIMENTAL
Intervention: Apixaban (10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months)
Number of subjects: 5395

Group type: COMPARATOR
Intervention: Conventional therapy (subcutaneous enoxaparin, followed by warfarin)
Number of subjects: 5395

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5395

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 5395
Study: 21981441

Group type: EXPERIMENTAL
Intervention: AWT(®) treatment with CELLACTOR(®) SC1 device, 8 sessions over 4 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: AWT(®) treatment
Number of subjects: 14
Study: 20112520

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) administered for 6 months prior to stapedectomy.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Stapedectomy without sodium fluoride (NaF) administration.
Number of subjects: 2
Study: 16929034

Group type: EXPERIMENTAL
Intervention: Full‐Serve version of McMaster PLUS
Number of subjects: 203

Group type: COMPARATOR
Intervention: Self‐Serve version of McMaster PLUS
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Full‐Serve and Self‐Serve versions of McMaster PLUS
Number of subjects: 203
Study: 15266196

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic treatment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Basal cortisol levels
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cortisol response pattern during stress
Number of subjects: 22
Study: 11642675

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 400 mg/kg body weight, total 30-45 g, administered in the follicular phase of a planned pregnancy, with a booster dose upon pregnancy diagnosis.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 150
Study: 9373733

Group type: EXPERIMENTAL
Intervention: BRMs
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study: 8436740

Group type: EXPERIMENTAL
Intervention: Intravenous urokinase alone
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) alone
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Combination of intravenous urokinase and rt-PA
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Immediate catheterization
Number of subjects: 575

Group type: COMPARATOR
Intervention: Deferred catheterization
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Fibrin specificity
Number of subjects: 575
Study: 3108758

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29511020

Group type: EXPERIMENTAL
Intervention: Temstem+AVH monitoring
Number of subjects: 100

Group type: COMPARATOR
Intervention: AVH monitoring
Number of subjects: 100
Study: 26615328

Group type: EXPERIMENTAL
Intervention: Nanoliposomal irinotecan plus fluorouracil and folinic acid
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Nanoliposomal irinotecan monotherapy
Number of subjects: 417

Group type: COMPARATOR
Intervention: Fluorouracil and folinic acid
Number of subjects: 417
Study: 24849843

Group type: EXPERIMENTAL
Intervention: Response-adaptive randomization scheme with minimal sufficient balancing design for baseline covariates and a cap on treatment allocation ratio shift.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control of important covariate imbalance and protection of treatment allocation randomness.
Number of subjects: 0
Study: 22747248

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham-acupuncture
Number of subjects: 33
Study: 19996730

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted therapy
Number of subjects: 0
Study: 18481113

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA) 150 mg/m(2) orally to achieve trough levels of 120-180 ng/ml
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cyclophosphamide pulses (CPH) 500 mg/m(2) per month intravenous
Number of subjects: 32
Study: 16136855

Group type: EXPERIMENTAL
Intervention: RSR13 (100 mg/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 7
Study: 11802257

Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 616

Group type: COMPARATOR
Intervention: Attention-control intervention
Number of subjects: 616
Study: 10075142

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg twice daily
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1054
Study: 7677456

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 169

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 169
Study: 2251872

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine with pertussis toxoid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine with pertussis toxoid and filamentous haemagglutinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 0
Study: 7423302

Group type: EXPERIMENTAL
Intervention: Abnormal fetal movements
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Abnormal HPL levels
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Both abnormal fetal movements and abnormal HPL levels
Number of subjects: 135
Study: 6681470

Group type: EXPERIMENTAL
Intervention: Phasic vergence training (stepwise tasks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Tonic vergence training (smooth, slow activities)
Number of subjects: 34
Study: 31091754

Group type: EXPERIMENTAL
Intervention: Collagen peptide supplementation (15 g daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Resistance exercise training (RET)
Number of subjects: 25
Study: 29300387

Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) results
Number of subjects: 202

Group type: COMPARATOR
Intervention: Family health history (FH) information alone
Number of subjects: 202
Study: 26864325

Group type: EXPERIMENTAL
Intervention: Computer interpretation messages (correct interpretation)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Computer interpretation messages (incorrect interpretation)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Correct computer interpretations
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Incorrect computer interpretations
Number of subjects: 254
Study: 25131042

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - 24 sessions of continuous 30 min treadmill exercise, intensity increased from 50%-70% of maximum heart rate.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control Group (CG) - No exercise intervention.
Number of subjects: 15
Study: 22234928

Group type: EXPERIMENTAL
Intervention: Aripiprazole (ARIP; 5-30 mg/day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ziprasidone (ZIP; 40-160 mg/day)
Number of subjects: 52
Study: 20800189

Group type: EXPERIMENTAL
Intervention: Online spaced education
Number of subjects: 724

Group type: COMPARATOR
Intervention: Web-based teaching (WBT)
Number of subjects: 724
Study: 17875084

Group type: EXPERIMENTAL
Intervention: Vitamin E at a dose of 100 mg/day for 3 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 58